Addendum...Of Interest this Week
Botox Shots Approved for Migraines, article in the Wall Street Journal. On Friday, the FDA approved Botox from Allergan as a treatment to prevent migraines, a little more than a month after the company agreed to pay $600 million to settle allegations that it had illegally marketed the drug for unapproved uses like headaches for years. Another article on this topic was published in the New York Times on October 15th.
When Drugs like Avandia Cause Problems they are suppose to Prevent, Oct.16th New York Times. In the past weeks, the FDA has noticed that two types of drugs that were suppose to prevent serious medical problems were, in fact, causing them.
The Court’s Pre-emption Test, article published on October 18th in the New York Times. Where state efforts to protect citizens and compensate victims don’t conflict with federal law, pre-emption should not be used as a weapon.
Breast Cancer seen as Riskier with Hormone, October 19th Wall street Journal and New York Times articles. Research found that hormone therapy for breast cancer speeds up the growth of the tumor.
Judge signals she’ll let Ruling on Military Policy stand, October 19th in the New York Times. Do we give the military the power to have absurd rules for fear of preventing a slippery slope or is there a way to have the military follow the constitution and still operate?
Payments to Doctors by most Pharma Companies still remains secret, published in Pro Publica on Oct. 20th. Consumers hoping to know more about the Doctor payments by Pharmaceutical companies will have to wait until 2013 for such disclosures to be made industry-wide.
Wall Street Journal article, MySpace apps leak user data, October 23rd. A Wall Street Journal investigation found that MySpace and popular applications of the networking site have been transmitting data to outside advertising companies that could be used to identify users.
For-profit Colleges Oppose Tighter Regulations. Part of a government plan to more closely regulate the for-profit education sector in the United States has been delayed, following an outcry from school supporters. Article in the New York Times, Oct.24th.
